Led by Dr. Dario Loparco, Breast Unit psycho-oncologist and DigniCap protocol manager at the ASL Brindisi Breast Unit,  the study is focused on breast cancer patients being treated with one of the most challenging chemotherapy regimens for hair retention -- epirubicin, cyclophosphamide and docetaxel (EC-T).

"DigniCap is quickly becoming standard of care in Italy and we are proud to have offered this life-changing therapy since 2015.  In a disease where so much is out of their control, cancer patients need to have the opportunity to preserve their hair during chemotherapy - and DigniCap gives them that choice," said Dr. Loparco.

Dr. Loparco and the oncology team at Antonio Perrino Hospital have published three previous clinical studies using the legacy DigniCap C3 system. Those studies demonstrated DigniCap success rates of 71 percent (http://dx.doi.org/10.2217/fon-2019-0066), 71.7 percent (http://dx.doi.org/10.1093/annonc/mdz240.026), and 72.8 percent (http://dx.doi.org/10.1093/annonc/mdy300.109) using a variety of chemotherapy regimens in breast cancer patients.

Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is listed as a treatment recommendation in the clinical practice guidelines published by European Society for Medical Oncology (https://www.annalsofoncology.org/article/S0923-7534(20)43157-6/fulltext) (ESMO), National Comprehensive Cancer Network (https://nccn.org/)® (NCCN) and Cancer Australia (https://www.guidancebreastcancer.gov.au/sites/default/files/guidelines/GEBC_Recommendations%20and%20practice%20points_Pdf_Sept%202020.pdf).